Non-small Cell Lung Cancer
A Study of Necitumumab (LY3012211) and Abemaciclib (LY2835219) in Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the safety and efficacy of two new medicines, (Necitumumab and Abemaciclib), administered in combination in participants with advanced lung cancer (stage IV non-small-cell lung cancer).
The results of this study are not yet available.
You may continue participation in this study for as long as your study doctor determines that you are benefiting from the study treatment.
Here you can find out a bit more about the requirements for volunteers who took part in this study
- Participant must have a diagnosis of non-small cell lung cancer stage IV confirmed by histology or cytology:
- Part A: non-small cell lung cancer stage IV (any type)
- Part B: non-small cell lung cancer stage IV (squamous and nonsquamous)
- Participant must have tumor tissue available for biomarker analyses
- Participant must not be currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device. Prior treatment with CDK4/6-targeting agents or necitumumab is not permitted
- Participant must not have undergone major surgery or received any investigational therapy in the 30-days prior to study enrollment
- Participant must not have undergone chest irradiation within 4 weeks prior to receiving study treatment
- Participant must not have brain metastases that are symptomatic
- Female participant must not be pregnant or breastfeeding
- Participant must not have a history of interstitial lung disease or an active non-infectious inflammation of the lung